MedTrace Logo

A Study of Imvotamab in Severe Systemic Lupus Erythematosus

NCT06041568 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2025-02-10

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and tolerability of imvotamab in patients with severe systemic lupus erythematosus who have failed prior therapies.

Participants will be given imvotamab through a vein (i.e., intravenously).

Conditions

Interventions

DRUG

Imvotamab

Administered intravenously

Sponsors & Collaborators

  • IGM Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Rebecca Kunder · IGM Biosciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-15
Primary Completion
2025-01-27
Completion
2025-01-27
FDA Drug
Yes

Countries

  • United States
  • Poland
  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06041568 on ClinicalTrials.gov